Clinical trial · Interventional
A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer
A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy
NCT01801930CI-TRIAL-00050368completedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the safety and tolerability of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OCV-103 and OCV-104 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Dose level 1
- interventionNames
- Drug: OCV-103 and OCV-104
- type
- EXPERIMENTAL
- label
- Dose level 2
- interventionNames
- Drug: OCV-103 and OCV-104
- type
- EXPERIMENTAL
- label
- Dose level 3
- interventionNames
- Drug: OCV-103 and OCV-104
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who have human leukocyte antigen (HLA)-A\*24:02 * Patients who have histologically-confirmed colorectal cancer (adenocarcinoma) * Patients with advanced or relapsed colorectal cancer who are refractory or intolerant to standard chemotherapy * Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1 at the time of enrollment in the trial. Exclusion Criteria: * Patients who are HIV antibody test positive * Patients with an active infection * Patients who have or are suspected to have CNS metastasis of colon cancer (such as metastatis of the brain)
References
Publications (1)
- DERIVEDTaniguchi H, Iwasa S, Yamazaki K, Yoshino T, Kiryu C, Naka Y, Liew EL, Sakata Y. Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer. Cancer Sci. 2017 May;108(5):1013-1021. doi: 10.1111/cas.13227. Epub 2017 May 11. PMID 28266765